|
| Study | Vaccine name | Age | Gender | Time from vaccination (days) | Vaccine type | Comorbidities | Presenting VA in affected eye (Snellen) | Vision at last visit in the affected eye | Intervention | Time until resolution (weeks) |
|
| Baglivo et al.[10] | Hepatitis B booster 3rd dose | 23 | F | 1 | Recombinant vaccines | None | 20/200 | Undisclosed-“recovery of vision” | None | 12 |
|
| Fine et al.[11] | Hepatitis A | 33 | M | 13 | Inactivated vaccines | None | 20/25-2 | 20/20 | None | 6 |
|
| Stangos et al. [12] | Hepatitis A and yellow fever | 50 | F | 10 | Inactivated vaccines | None | 20/40 | 20/20 | None | 6 |
|
| Cohen [9] | Human papilloma virus and meningococca | 17 | F | 30 | Recombinant vaccines | None | 20/200 | 20/20 | None | 8 |
|
| Goyal et al. [13] | Influenza | 53 | M | 10 | Undisclosed | Hepatitis B and C infection, polysubstance abuse | 20/25-2 | 20/20 | None | 4 |
|
| Ogino et al. [8] | Human papilloma virus (Cervarix®, Glaxo Smith Kline) 2nd dose | 16 | F | 14 | Recombinant vaccines | None | 20/16 | 20/16 | None initially, betamethasone and antihistamine later for peripheral vascular leakage and associated visual field constriction | Retinal lesions resolved at 2 months; worsening peripheral vision loss for 2 years |
|
| Abou-Samra et al. [14] | Influenza | 27 | F | 14 | Undisclosed | Stevens-Johnson syndrome, Wolff-Parkinson-White, vesicourethral reflux, mild chronic kidneydisease, endometriosis, fibroadenomas, depression with anxiety | 20/25-2 | Undisclosed | None | 8 |
|
| Yang et al. [15] | Rabies 3rd dose | 33 | F | 14 | Embryonated-egg vaccine | None | 20/20 | 20/20 | Retrobulbar triamcinolone acetonide 40 mg | Partially resolved at 8 weeks |
|
| Ng et al. [2] | Influenza (Flucelvax Quadrivalent® Seqirus) | 34 | M | 14 | Inactivated vaccines | None | 20/20+2 | 20/16 | None | 4 |
|
| Rabinovitch et al. [16] | COVID-19 2nd dose | 39 | M | 5 | mRNA vaccines | None | 20/32 | 20/20 | None | 8 |
| 28 | F | 30 | mRNA vaccines | None | 20/32 | 20/20 | None | 8 |
|
| Xu and Shen [17] | COVID-19 1st dose | 49 | F | 2 | Inactivated vaccines | MEWDS | 20/100 | 20/20 | Oral prednisone | 8 |
|
| Inagawa et al. [18] | COVID-19 1st dose | 30 | F | 6 | mRNA vaccines | None | 20/20 | 20/20 | Topical corticosteroid | 8 |
|
| Yasuda et al. [19] | COVID-19 2nd dose | 67 | F | 1 | mRNA vaccines | None | 20/100 | 20/25 | None | 2 |
|
| Lin and Hsieh [20] | COVID-19 1st dose | 36 | F | 2 | Recombinant vaccines | None | 20/25 | 20/20 | None | 4 |
|
| Tomishige et al. [21] | COVID-19 1st dose | 38 | F | 7 | Inactivated vaccines | None | 20/400 | 20/20 | Oral prednisone | 4 |
|
| Smith et al. [22] | COVID-19 2nd dose | 15 | M | 14 | mRNA vaccines | None | 20/100 | 20/20 | Oral prednisone | 2 |
| 21 | F | 21 | mRNA vaccines | None | 20/60 | 20/20 | Oral prednisone | 2 |
|
| Bolletta et al. [23] | COVID-19 2nd dose | 53 | M | 28 | mRNA vaccines | None | 20/25 | 20/20 | None | Undisclosed time but complete resolution |
| COVID-19 1st dose | 18 | F | 4 | mRNA vaccines | None | 20/66 | 20/20 | None | Undisclosed time but complete resolution |
| COVID-19 1st dose | 48 | M | 7 | mRNA vaccines | None | 20/400 | 20/20 | None | Undisclosed time but complete resolution |
|
| Alhabshan and Scales [24] | COVID-19 3rd dose | 71 | F | 3 | mRNA vaccines | Retinal tear was treated with laser barricade; hysterectomy, hypercholesterolemia | 20/30 | Undisclosed | None | 6 |
|
| Gargouri et al.[25] | COVID-19 1st dose | 23 | F | 10 | mRNA vaccines | SARS-CoV-2 infection | 20/20 | 20/20 | None | 6 |
| 40 | M | 7 | mRNA vaccines | None | 20/25 | Undisclosed | None | 6 |
|
| 41.7% developed after receiving the second or the third dose vaccination | Mean:35.9
Median: 33.5
Range:15–71 | 66.7% female | Mean:11.1
Median: 8.5
Range: 1–30 | 91.7% of vaccines are inactive | 79.2% none | Mean: 20/34
Median: 20/30
Range: 20/400–20/16 | Mean: 20/20
Median: 20/20
Range: 20/25–20/16 | 70.8% none | Mean: 5.9
Median: 6
Range: 2–12 |
|
